10-Q · May 7, 2026
BridgeBio reported Q1 2026 revenues of $194.5 million, which beat estimates of $178.8 million, and net product revenue from Attruby increased significantly to $180.6 million. However, the company reported a diluted EPS…
Earnings analysis · 10-Q
BBIO earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
BridgeBio delivered strong Q2 revenue of $243.7 million, up approximately 25% sequentially and 119% year over year, with $222.4 million from Attruby. Losses improved year over year and liquidity totaled $720.2 million,…
Read full summary
BridgeBio delivered strong Q2 revenue of $243.7 million, up approximately 25% sequentially and 119% year over year, with $222.4 million from Attruby. Losses improved year over year and liquidity totaled $720.2 million, but EPS of negative $0.78 missed consensus and the company continues to carry substantial debt, royalty obligations and operating losses. The outlook is balanced: management expects liquidity plus Attruby proceeds to fund operations for at least 12 months, while potential royalty increases, pricing reforms, convertible-note exposure and dilution remain material risks.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.78
What stood out
-
Attruby drives strong revenue growth
Revenue increased to $243.7 million from $195 million in the prior quarter and $111 million in the prior-year quarter, representing approximately 25% sequential growth and 119% year-over-year growth. Attruby contributed $222.4 million of product revenue.
-
EPS improved year over year
Reported EPS was negative $0.78, improving from negative $0.84 in Q1 2026 and negative $0.95 in Q2 2025, although it missed the $0.59 consensus loss estimate by $0.19.
-
Net loss narrowed
Net loss narrowed to $155.9 million from $183.8 million in the year-ago quarter; the six-month net loss was $322.4 million versus $353.4 million in the prior-year period.
-
Liquidity supports near-term operations
Liquidity was $720.2 million in cash, cash equivalents and marketable securities, with working capital of $202.5 million. Management expects these resources plus Attruby proceeds to fund operations through at least the next 12 months.
-
Secondary supply source added
The company has taken delivery of commercial Attruby and Beyonttra drug product from a secondary supplier and expects the tablets to enter finished-goods inventory later in 2026 after packaging.
-
No reported control deficiencies
Management reported effective disclosure controls as of June 30, 2026, and stated that no change in internal control over financial reporting materially affected, or was reasonably likely to materially affect, controls during the quarter.
What to watch
-
Heavy debt and royalty obligations
Total consolidated indebtedness was $2.5 billion, including $550.0 million of 2027 Notes, $747.5 million of 2029 Notes, $575.0 million of 2031 Notes and $632.5 million of 2033 Notes. Deferred royalty obligations were an additional $908.7 million.
-
Attruby royalty burden may rise
The Funding Agreement currently requires royalty interest payments equal to 5% of global Attruby net sales, with the rate potentially increasing to a maximum of 10% in 2027. The agreement has a $950.0 million payment cap.
-
Convertible notes may pressure liquidity
The 2027 and 2031 Notes became convertible for a limited period beginning July 1, 2026 and remain convertible through September 30, 2026, potentially requiring cash settlement and reducing liquidity.
-
Repurchases compete with cash needs
The company approved a stock repurchase program of up to $500.0 million but had repurchased 1,904,001 shares for $127.4 million through June 30, 2026, leaving $372.5 million available. Capital deployment could compete with funding needs given the $322.4 million six-month net loss.
-
New preferred stock creates dilution
A new Series A preferred stock issuance comprised 933,900 shares that are initially convertible into 6,777,704 common shares. Conversion could dilute common shareholders, and the preferred stock ranks senior to common stock for dividends and liquidation.
-
Pricing reform threatens Attruby economics
The filing highlights heightened drug-pricing uncertainty: proposed GLOBE and GUARD models could impose additional Medicare rebates, with proposed testing periods beginning October 1, 2026 and January 1, 2027. Attruby's U.S. list price increased from $18,759.12 to $19,790.00 for a 28-day supply in January 2026.
Management's outlook
No numeric revenue or EPS guidance was provided in the 10-Q. Management stated that cash, cash equivalents, marketable securities and Attruby proceeds are expected to fund operations through at least the next 12 months from filing.
Earlier filings 4
10-K · February 24, 2026
BridgeBio’s 10‑K describes a transition to a commercial-stage portfolio anchored by Attruby (acoramidis), which generated $362.4 million in U.S. net product revenues in 2025 and drove stronger quarterly company revenue…
10-Q · August 5, 2025
BridgeBio reported Q2 revenue of $110.565M (three months ended June 30, 2025) driven by first product sales (net product revenue $71.501M) and higher license/services revenue ($37.440M), materially above Q2 2024 revenue…
10-Q · November 12, 2024
BridgeBio reported Q3 revenue of $2,732,000 and a GAAP net loss attributable to common stockholders of $162,040,000 (net loss per share -$0.86). Revenue declined vs. year-ago ($4,091,000) but improved versus Q2 2024…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.